Z Shi1, N An, B M Lu, N Zhou, S L Yang, B Zhang, C Y Li, Z J Wang, F Wang, C F Wu, J K Bao. 1. School of Life Sciences & Key Laboratory of Bio-resources, Ministry of Education, Sichuan University, Chengdu, 610064, China; School of Life Sciences, Guizhou Normal University, Guiyang, 550001, China.
Abstract
OBJECTIVES: Protein kinases orchestrate activation of signalling cascades in response to extra- and intracellular stimuli for regulation of cell proliferation. They are directly involved in a variety of diseases, particularly cancers. Systems biology approaches have become increasingly important in understanding regulatory frameworks in cancer, and thus may facilitate future anti-cancer discoveries. Moreover, it has been suggested and confirmed that high-throughput virtual screening provides a novel, effective way to reveal small molecule protein kinase inhibitors. Accordingly, we aimed to identify kinase targets and novel kinase inhibitors. MATERIALS AND METHODS: A series of bioinformatics methods, such as network construction, molecular docking and microarray analyses were performed. RESULTS: In this study, we computationally constructed the appropriate global human protein-protein interaction network with data from online databases, and then modified it into a kinase-related apoptotic protein-protein interaction network. Subsequently, we identified several kinases as potential drug targets according to their differential expression observed by microarray analyses. Then, we predicted relevant microRNAs, which could target the above-mentioned kinases. Ultimately, we virtually screened a number of small molecule natural products from Traditional Chinese Medicine (TCM)@Taiwan database and identified a number of compounds that are able to target polo-like kinase 1, cyclin-dependent kinase 1 and cyclin-dependent kinase 2 in HeLa cervical carcinoma cells. CONCLUSIONS: Taken together, all these findings might hopefully facilitate discovery of new kinase inhibitors that could be promising candidates for anti-cancer drug development.
OBJECTIVES: Protein kinases orchestrate activation of signalling cascades in response to extra- and intracellular stimuli for regulation of cell proliferation. They are directly involved in a variety of diseases, particularly cancers. Systems biology approaches have become increasingly important in understanding regulatory frameworks in cancer, and thus may facilitate future anti-cancer discoveries. Moreover, it has been suggested and confirmed that high-throughput virtual screening provides a novel, effective way to reveal small molecule protein kinase inhibitors. Accordingly, we aimed to identify kinase targets and novel kinase inhibitors. MATERIALS AND METHODS: A series of bioinformatics methods, such as network construction, molecular docking and microarray analyses were performed. RESULTS: In this study, we computationally constructed the appropriate global human protein-protein interaction network with data from online databases, and then modified it into a kinase-related apoptotic protein-protein interaction network. Subsequently, we identified several kinases as potential drug targets according to their differential expression observed by microarray analyses. Then, we predicted relevant microRNAs, which could target the above-mentioned kinases. Ultimately, we virtually screened a number of small molecule natural products from Traditional Chinese Medicine (TCM)@Taiwan database and identified a number of compounds that are able to target polo-like kinase 1, cyclin-dependent kinase 1 and cyclin-dependent kinase 2 in HeLa cervical carcinoma cells. CONCLUSIONS: Taken together, all these findings might hopefully facilitate discovery of new kinase inhibitors that could be promising candidates for anti-cancer drug development.
Authors: P Therese Lang; Scott R Brozell; Sudipto Mukherjee; Eric F Pettersen; Elaine C Meng; Veena Thomas; Robert C Rizzo; David A Case; Thomas L James; Irwin D Kuntz Journal: RNA Date: 2009-04-15 Impact factor: 4.942
Authors: Zheng Shi; Chun-yang Li; Si Zhao; Yang Yu; Na An; Yong-xi Liu; Chuan-fang Wu; Bi-song Yue; Jin-ku Bao Journal: Cancer Lett Date: 2013-06-18 Impact factor: 8.679
Authors: David Olmos; Douglas Barker; Rohini Sharma; Andre T Brunetto; Timothy A Yap; Anne B Taegtmeyer; Jorge Barriuso; Hanine Medani; Yan Y Degenhardt; Alicia J Allred; Deborah A Smith; Sharon C Murray; Thomas A Lampkin; Mohammed M Dar; Richard Wilson; Johann S de Bono; Sarah P Blagden Journal: Clin Cancer Res Date: 2011-04-01 Impact factor: 12.531
Authors: Dorothea Rudolph; Martin Steegmaier; Matthias Hoffmann; Matthias Grauert; Anke Baum; Jens Quant; Christian Haslinger; Pilar Garin-Chesa; Günther R Adolf Journal: Clin Cancer Res Date: 2009-04-21 Impact factor: 12.531
Authors: Hanna S Radomska; Meritxell Alberich-Jordà; Britta Will; David Gonzalez; Ruud Delwel; Daniel G Tenen Journal: J Clin Invest Date: 2012-07-17 Impact factor: 14.808
Authors: Alejandra Idan Valencia-Cruz; Laura I Uribe-Figueroa; Rodrigo Galindo-Murillo; Karol Baca-López; Anllely G Gutiérrez; Adriana Vázquez-Aguirre; Lena Ruiz-Azuara; Enrique Hernández-Lemus; Carmen Mejía Journal: PLoS One Date: 2013-01-31 Impact factor: 3.240
Authors: Jianhui Shi; Gang An; Ying Guan; Tianli Wei; Zhibin Peng; Min Liang; Yansong Wang Journal: Cancer Cell Int Date: 2019-04-23 Impact factor: 5.722